We Expect WuXi Biologics' Growth to Lag Peers
We forecast WuXi's revenue growth to be slower than that of other well-established peers. The risk is high that the US Biosecure Act will become law, and we expect global pharmaceutical or ...
Vietnam Investment Review on MSN5d
WuXi Biologics Posts Strong 2024 Results Forecasts Rapid Growth in 2025
Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...
Endpoints News5d
WuXi Bi­o­log­ics’ li­cens­ing deals help off­set Biose­cure threat in the US
WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...
Fierce Pharma5d
Contractors WuXi Bio, WuXi XDC eye continued growth after logging solid performances in 2024
Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...